Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Sep 1.

Published in final edited form as: J Am Acad Dermatol. 2018 Mar 1;79(3):487–494. doi: 10.1016/j.jaad.2018.02.034

Subject 9 at baseline demonstrating widespread thin pink plaques with classic ‘islands of sparing’ (a) and after 6 months of treatment with ustekinumab (b). He demonstrated near complete clearance after 2 monthly doses of 0.6 mg/kg but in order to maintain this he ultimately required ustekinumab 1.2 mg/kg every 8 weeks.

Subject 9 at baseline demonstrating widespread thin pink plaques with classic ‘islands of sparing’ (a) and after 6 months of treatment with ustekinumab (b). He demonstrated near complete clearance after 2 monthly doses of 0.6 mg/kg but in order to maintain this he ultimately required ustekinumab 1.2 mg/kg every 8 weeks.